Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma.
Hartmann JT, Kopp HG, Gruenwald V, Piperno-Neumann S, Kunitz A, Hofheinz R, Mueller L, Geissler M, Horger M, Fix P, Chemnitz JM, Neise M, Wehler T, Zander I, Eckert R, Hann von Weyhern C, Bauer S, Mayer F; German Sarcoma Group within the Working Group Medical Oncology (AIO) of the German Cancer Society/AIO-STS-002, Arbeitsgemeinschaft Internistische Onkologie der Deutschen Krebsgesellschaft e.V. Hartmann JT, et al. Among authors: kopp hg. Eur J Cancer. 2020 Jan;124:152-160. doi: 10.1016/j.ejca.2019.10.016. Epub 2019 Nov 28. Eur J Cancer. 2020. PMID: 31785463 Clinical Trial.
ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
Böpple K, Oren Y, Henry WS, Dong M, Weller S, Thiel J, Kleih M, Gaißler A, Zipperer D, Kopp HG, Aylon Y, Oren M, Essmann F, Liang C, Aulitzky WE. Böpple K, et al. Among authors: kopp hg. Cell Death Dis. 2024 Apr 24;15(4):290. doi: 10.1038/s41419-024-06674-x. Cell Death Dis. 2024. PMID: 38658567 Free PMC article.
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Stratmann JA, Althoff FC, Doebel P, Rauh J, Trummer A, Hünerlitürkoglu AN, Frost N, Yildirim H, Christopoulos P, Burkhard O, Büschenfelde CMZ, Becker von Rose A, Alt J, Aries SP, Webendörfer M, Kaldune S, Uhlenbruch M, Tritchkova G, Waller CF, Rittmeyer A, Hoffknecht P, Braess J, Kopp HG, Grohé C, Schäfer M, Schumann C, Griesinger F, Kuon J, Sebastian M, Reinmuth N. Stratmann JA, et al. Among authors: kopp hg. Eur J Cancer. 2024 Apr;201:113911. doi: 10.1016/j.ejca.2024.113911. Epub 2024 Feb 14. Eur J Cancer. 2024. PMID: 38377774 Free article.
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade.
Charpidou A, Gerotziafas G, Popat S, Araujo A, Scherpereel A, Kopp HG, Bironzo P, Massard G, Jiménez D, Falanga A, Kollias A, Syrigos K. Charpidou A, et al. Among authors: kopp hg. Cancers (Basel). 2024 Jan 20;16(2):450. doi: 10.3390/cancers16020450. Cancers (Basel). 2024. PMID: 38275891 Free PMC article. Review.
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: kopp hg. Eur J Cancer. 2024 Mar;199:113556. doi: 10.1016/j.ejca.2024.113556. Epub 2024 Jan 17. Eur J Cancer. 2024. PMID: 38271745 Free article.
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Lüders H, Kollmeier J, Kulhavy J, Kemper M, Reinmuth N, Röper J, Janning M, Sommer L, Aguinarte L, Koch M, Wiesweg M, Wesseler C, Waller CF, Kauffmann-Guerrero D, Stenzinger A, Stephan-Falkenau S, Trautmann M, Lassmann S, Tiemann M, Klauschen F, Sebastian M, Griesinger F, Wolf J, Loges S, Frost N; National Network Genomic Medicine Lung Cancer (nNGM) Collaborator Group. Bischoff P, et al. J Thorac Oncol. 2023 Dec 13:S1556-0864(23)02423-1. doi: 10.1016/j.jtho.2023.12.015. Online ahead of print. J Thorac Oncol. 2023. PMID: 38096950 Free article.
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Goetze TO, Hofheinz RD, Gaiser T, Schmalenberg H, Strumberg D, Goekkurt E, Angermeier S, Zander T, Kopp HG, Pink D, Siegler G, Schenk M, de Vita F, Galizia G, Maiello E, Bechstein WO, Elshafei M, Loose M, Sookthai D, Brulin T, Pauligk C, Homann N, Al-Batran SE. Goetze TO, et al. Among authors: kopp hg. Int J Cancer. 2023 Jul 1;153(1):153-163. doi: 10.1002/ijc.34495. Epub 2023 Mar 23. Int J Cancer. 2023. PMID: 36883420 Clinical Trial.
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome.
Hamacher R, Liu X, Schuler MK, Hentschel L, Schöffski P, Kopp HG, Bauer S, Kasper B, Lindner L, Chemnitz JM, Crysandt M, Stein A, Steffen B, Richter S, Egerer G, Ivanyi P, Kunitz A, Grünwald V. Hamacher R, et al. Among authors: kopp hg. Eur J Cancer. 2023 Mar;181:145-154. doi: 10.1016/j.ejca.2022.12.012. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36657323 Clinical Trial.
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.
Roggia C, Armeanu-Ebinger S, Gschwind A, Seibel-Kelemen O, Hertler S, Faust U, Liebmann A, Haack TB, Neumann M, Bonzheim I, Forschner A, Kopp HG, Herster F, Hartkopf A, Bitzer M, Malek NP, Brecht IB, Ruhm K, Möller Y, Löwenheim H, Ossowski S, Rieß OH, Schroeder C. Roggia C, et al. Among authors: kopp hg. Eur J Cancer. 2023 Jan;179:48-55. doi: 10.1016/j.ejca.2022.11.003. Epub 2022 Nov 8. Eur J Cancer. 2023. PMID: 36495689
133 results